Seattle Genetics, Inc.

Medimmune Limited

Seagen Inc.

Spirogen Sarl

Scott C Jeffrey

Patrick J Burke

Philip Wilson Howard

Peter Senter

Django Sussman

Brian E Toki

Dennis R Benjamin

Stephen C Alley

Arnaud Charles Tiberghien

Svetlana Doronina

Toni Beth Kline

Luke Masterson

Damon L Meyer

Maureen Ryan

May Kung Sutherland

Andrew Waight

Ryan Lyski

Robert Kolakowski

Heather Van Epps

Uland Lau

Byron Hua Kwan

Arnaud Tiberghien

Joseph Z Hamilton

Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.

Anti-PD-L1 antibodies and antibody-drug conjugates

Antibody conjugates with camptothecin compounds are described, with methods of use and preparations.

Camptothecin conjugates

The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation

The present invention provides Ligand-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.

Methylene carbamate linkers for use with targeted-drug conjugates

The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

CD33 antibodies and use of same to treat cancer

Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.

Targeted pyrrolobenzodiazapine conjugates

This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.

Pyrrolobenzodiazepines and targeted conjugates

A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein:(a) Ris H, and Ris OH, OR, where Ris saturated Calkyl;(b) Rand Rform a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or(c) Ris H and Ris SOM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.

Ligand Drug conjugate compounds comprising a &#x3b2;-glucuronide-based linker and methods of using such compounds are provided.

&#x3b2;-glucuronide-linker drug conjugates

Pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.

Pyrrolobenzodiazepines used to treat proliferative diseases

A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein:

Growing community of inventors

Bothell, WA, United States of America

Scott C Jeffrey